Abveris appoints Tracey Mullen as Chief Operating Officer

By Ryan Kelly - January 24, 2019

Canton, MA – January 24, 2019 – Abveris, Inc. today announced that Director of Antibody Discovery Operations Tracey Mullen has been appointed Chief Operating Officer, a new position within Abveris. Mullen previously oversaw laboratory operations and will continue to report to Garren Hilow, CEO of Abveris.

“Tracey is an outstanding member of the Abveris team who consistently delivers results. Her promotion to Chief Operating Officer is in recognition of the consistency and accountability she has demonstrated as Director of Operations,” said Garren Hilow, CEO. “I have tremendous confidence in Tracey’s ability to drive the future of innovation at Abveris with her laser-focus on operational excellence.”

An MIT graduate, Mullen joined Abveris in 2018 after five years of scientific employ at Biogen. During her time at Biogen, Mullen was engaged in biotherapeutics discovery work using diverse platform technologies.

In her free time, Mullen is an avid rock climber who can be found traveling to the most distant regions of the country with her husband and Siberian husky in search of exciting climbing routes.



We can take your antibody project from concept to antibody clone.

We execute rapid reagent discovery services to enable speedy target validation. Share your target ID and we'll deliver a validated panel of reagents for you to choose from with affinity characterization and antibody sequence included.

Click below to schedule a call with an Abveris scientist today.


We promise that we won't SPAM you.